clinical trial · NCT07614776
A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration
Neovascular Age-related Macular DegenerationnAMDABP 938 8 mgAflibercept (US) 8 mg
brief summary
The aim of this trial is to demonstrate similarity in efficacy between ABP 938 8 mg and aflibercept (US) 8 mg by evaluating the change in best corrected visual acuity (BCVA) in participants with neovascular age-related macular degeneration (nAMD)
started
May 27, 2026
primary completion
Jul 31, 2027
completion
Jan 12, 2028
last updated
Aug 17, 2026
official title
A Randomized, Double-masked, Comparative Clinical Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 938 8 mg Versus EYLEA® HD (Aflibercept) Delivered Via Intravitreal Injection in Participants With Neovascular Age-related Macular Degeneration
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol